A Safety and Efficacy Study of Intravenous E5564 in Patients With Severe Sepsis

Sepsis is a serious condition where there is inflammation and damage to body tissue, usually caused by an infection. This infection can lead to decreased function of vital body organs and in some cases may lead to permanent health problems or death.

Much of the injury is due to endotoxin, a harmful substance produced by certain types of bacteria. An endotoxin antagonist is designed to block the effects of endotoxin.

This study is designed to study the safety and efficacy when treating patients with severe sepsis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Sepsis Bacteremia Endotoxemia Infection Infections Inflammation Pathologic Processes Pathological Conditions, Signs and Symptoms Sepsis Syndrome Septicemia Shock Shock, Septic Systemic Inflammatory Response Syndrome Toxemia

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Mobile, Alabama, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Presently admitted, or about to be transferred, to the ICU.
Women of Child-bearing potential must have a negative serum (or urine) hCG assay within 24 hours prior to drug administration.
Any Race.
Severe Sepsis [newly developed respiratory failure, refractory shock, renal dysfunction, hepatic dysfunction, or metabolic acidosis and at least three signs of SIRS (systematic inflammatory response syndrome)].
Objective signs of infection likely to be caused by a bacterial or fungal pathogen.
Patients must receive study medication within 8 to 12 hours of recognition of the initial sepsis-related organ failure.
APACHE Predicted risk of mortality score between 20% and 80%.
An intent by physicians and family to aggressively treat the patient for the 28 day study period.

Exclusion criteria

Cardiogenic or hypovolemic shock.
Acute third degree burns involving >20% of body surface.
Recipients of non-autologous organ transplants within the past year.
Pregnancy.
Chronic vegetative state.
Uncontrolled serious hemorrhage (.2 units of blood/platelets in the previous 24 hours). Patients may be considered for enrollment if bleeding has stopped and patients are still otherwise qualified.
Unwilling or unable to be fully evaluated for all follow-up visits.
Patients who are classified as "Do not resusitate" or "Do not treat."
Patients who develop severe sepsis <36 hours post trauma or post-surgery. Patients may be considered for enrollment >36 hours post-trauma or post-surgery, if they meet other inclusion criteria.
Patients with a predicted risk of mortality score of <20% or >80% after recognition of qualifying organ failure.
Patients with a predicted risk of mortality of <51% for whom Xigris® use is planned.

Treatment and study plan

E5564

Drug

Sponsors and collaborators

Lead sponsor

Eisai Inc.

Industry

Registry information

Official study title

A Double-Blind, Placebo-Controlled Study of E5564, A Lipid A Antagonist, Administered by Twice Daily Infusions in Patients With Severe Sepsis

Important dates

Study start: 2001
Study completion: 2005
First posted: Sep 20, 2002
Registry last updated: Dec 12, 2005

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed